UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4590683 (State or other juris ...

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on i ...

Company Performance - Avidity Biosciences reported a quarterly loss of $0.90 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.79 per share a year ago, indicating a negative earnings surprise of -2.27% [1] - The company posted revenues of $1.57 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.68%, and down from $3.54 million in the same quarter last year [2] - Over the last four quarters, Avidity has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Market Comparison - Avidity Biosciences shares have declined approximately 10% since the beginning of the year, while the S&P 500 has seen a decline of -4.3% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.86 on revenues of $2.1 million, and for the current fiscal year, it is -$3.90 on revenues of $9.25 million [7] - The estimate revisions trend for Avidity Biosciences is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Avidity belongs, is currently in the top 33% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8]

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero’s 2025 annual meeting of stockholders. Since Janu ...

Spero Therapeutics (SPRO) Q4 2024 Earnings Call March 27, 2025 10:33 PM ET Company Participants Shai Biran - Investor RelationsEsther Rajavelu - Interim CEO & CFOTimothy Keutzer - COO Conference Call Participants Gavin Clark-Gartner - AnalystAthena Chin - Biotechnology Equity Research Analyst Operator Good afternoon, and welcome to the Spirit Therapeutics Fourth Quarter and Full Year twenty twenty four Earnings Conference Call. At this time, all participants are in listen only mode. Following the company's ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief Executive Officer, Chief Financial Officer Tim Keutzer - Chief Operating Officer Conference Call Participants Gavin Clarke-Gartner - Evercore ISI Athena Chin - TD Cowen Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all par ...

Company Performance - Spero Therapeutics reported a quarterly loss of $0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and a significant decline from earnings of $0.96 per share a year ago, indicating an earnings surprise of -8.57% [1] - The company posted revenues of $15.04 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 21.32%, but this represents a decline from year-ago revenues of $73.52 million [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Spero Therapeutics shares have declined approximately 13.6% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.33 on $11 million in revenues, and for the current fiscal year, it is -$0.79 on $60 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____to____ Commission file number 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4590683 State or other juri ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprior ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to d ...